Researchers at a U.S. biotechnology company are optimistic about a new blood test that they hope can make early-stage cancer diagnosis affordable and accessible globally.
California-based Novelna has shown initial positive results in the test's ability to detect 18 types of cancers.
Ashkan Afshin, the chief executive officer of the company, told Devex that they hope to “make these cancer screenings scalable and affordable for everyone.”
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Sara Jervingsarajerving
Sara Jerving is a Senior Reporter at Devex, where she covers global health. Her work has appeared in The New York Times, the Los Angeles Times, The Wall Street Journal, VICE News, and Bloomberg News among others. Sara holds a master's degree from Columbia University Graduate School of Journalism where she was a Lorana Sullivan fellow. She was a finalist for One World Media's Digital Media Award in 2021; a finalist for the Livingston Award for Young Journalists in 2018; and she was part of a VICE News Tonight on HBO team that received an Emmy nomination in 2018. She received the Philip Greer Memorial Award from Columbia University Graduate School of Journalism in 2014.
